Rat epidermal growth factor composition and application thereof in preparation of medicine for treating cancer

The murine epidermal growth factor compositions isolated and prepared into various dosage forms by non-reducing SDS-PAGE, filling the gap in cancer treatment of natural extraction compositions, achieving efficient inhibition of gastric cancer cells, and being harmless to normal cells. It demonstrates safe and effective anti-tumor effects.

CN118903381AInactive Publication Date: 2024-11-08ZHEJIANG HUAJIN YIKE BIOPHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410967665.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has not yet used naturally extracted murine epidermal growth factor compositions in cancer treatment, especially in the treatment of gastric cancer.

Method used

The murine epidermal growth factor composition isolated by non-reducing SDS-PAGE, with molecular weights of 40-55kDa, 25-35kDa and 10-15kDa, were prepared into preparations including injection, topical, oral, sustained release, etc., and combined with pharmacy Acceptable carriers and excipients for anti-tumor treatment.

Benefits of technology

The composition shows high-efficiency anti-tumor activity, has a significant inhibitory effect on gastric cancer cells, and has no promotion or inhibitory effect on normal cells, and has the potential of safe and effective anti-tumor drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903381A_ABST
    Figure CN118903381A_ABST
Patent Text Reader

Abstract

The invention discloses a mouse epidermal growth factor composition and application of the mouse epidermal growth factor composition in preparation of a medicine for treating cancer, the mouse epidermal growth factor composition has three bands in non-reducing SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), and the measured molecular weights are 40-55 kDa, 25-35 kDa and 10-15 kDa respectively. The mouse epidermal growth factor composition is obtained by carrying out crude extraction and cation exchange chromatography on a mouse submaxillary gland, eluting a target peak and then carrying out ultrafiltration purification, has an obvious killing effect on gastric cancer cells, and can be developed into a preparation of a medicine for treating gastric cancer. The method has the advantages of few steps in the technological process, simplicity and convenience in operation, no need of special reagents, extremely high social and economic values and development of the application prospect of the mouse epidermal growth factor composition in the field of cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a preparation method and application of a pharmaceutical composition in the medical field, and in particular to a mouse epidermal growth factor composition and application thereof in preparing a drug for treating cancer. Background Art

[0002] Mouse epidermal growth factor (Epidermal Growth Factor, EGF) is a biologically active substance, EGF binds to a specific receptor on the cell surface, namely, the epidermal growth factor receptor (EGFR), triggers the signal transduction pathway, and then regulates a variety of cell physiological processes. However, at present, there is no natural extraction of mouse epidermal growth factor composition used in cancer treatment. Summary of the invention

[0003] The first purpose of the present invention is to provide an application of a mouse epidermal growth factor composition in the preparation of a drug for treating cancer, thereby filling the gap in the use of a naturally extracted mouse epidermal growth factor composition for cancer treatment.

[0004] The technical solution adopted by the present invention is as follows:

[0005] The invention discloses an application of a mouse epidermal growth factor composition in preparing a drug for treating cancer. The mouse epidermal growth factor composition presents three bands in non-reducing SDS-PAGE, and the measured molecular weights are 40-55 kDa, 25-35 kDa, and 10-15 kDa, respectively.

[0006] Preferably, the cancer is gastric cancer.

[0007] The second object of the present invention is to provide a mouse epidermal growth factor composition, which presents three bands in non-reducing SDS-PAGE, and the measured molecular weights are 40-55 kDa, 25-35 kDa, and 10-15 kDa, respectively.

[0008] The third object of the present invention is to provide a mouse epidermal growth factor preparation, which contains an effective dose of the above mouse epidermal growth factor composition.

[0009] Preferably, the preparation further comprises an auxiliary material or a pharmaceutically acceptable carrier.

[0010] Preferably, the dosage form of the mouse epidermal growth factor preparation includes an injection preparation, an external preparation, an oral preparation, a sustained-release preparation or a controlled-release preparation.

[0011] The administration method of the preparation of the present invention is not particularly limited, and representative administration methods include (but are not limited to): parenteral (intravenous, intramuscular or subcutaneous), oral, external and local administration.

[0012] Solid dosage forms for oral administration include capsules, tablets, pills, powders, lyophilized powders and granules. In these solid dosage forms, the mouse epidermal growth factor composition stock solution is mixed with at least one conventional inert excipient (or carrier). In capsules, tablets, lyophilized powders and pills, the dosage form may also contain a buffer.

[0013] Solid dosage forms, such as tablets, sugar pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They can contain opacifiers, and the release of the mouse epidermal growth factor composition solution or compound in such a composition can be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and wax substances. If necessary, the mouse epidermal growth factor composition solution can also be formed into microcapsules with one or more of the above-mentioned excipients.

[0014] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the mouse epidermal growth factor composition stock solution, the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers.

[0015] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0016] The dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays, lyophilized powders and inhalants. The active ingredient is mixed under sterile conditions with physiologically acceptable adjuvants, carriers and any preservatives, buffers, or propellants that may be required if necessary.

[0017] The preparation of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds.

[0018] The fourth object of the present invention is to provide an anti-cancer drug, the active ingredient of which includes the above-mentioned mouse epidermal growth factor composition.

[0019] Preferably, the drug further comprises an auxiliary pharmaceutically acceptable carrier.

[0020] Preferably, the cancer is gastric cancer.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The invention provides a naturally extracted mouse epidermal growth factor composition, which has high-efficiency anti-tumor activity and has no promoting or inhibiting effect on normal mouse fibroblasts, and has the potential to become a safe and effective anti-tumor drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the spectrum of cation exchange chromatography I in Example 1, wherein the target peak is sample collection-sample collection end.

[0024] Figure 2 This is the spectrum of cation exchange chromatography II of Example 1, wherein the target peak is E5.

[0025] Figure 3 This is a non-reducing SDS-PAGE image of the mouse epidermal growth factor composition (E5-P) of Example 1.

[0026] Figure 4 The effect of the mouse epidermal growth factor composition (E5-P) of Application Example 1 on N87 human gastric cancer cells.

[0027] Figure 5 This is the effect of pure mouse epidermal growth factor (mEGF) of Comparative Example 1 on 3T3 mouse fibroblasts.

[0028] Figure 6 This is the effect of pure mouse epidermal growth factor (mEGF) in Comparative Example 2 on N87 human gastric cancer cells. DETAILED DESCRIPTION

[0029] The features of the present invention are described below in conjunction with embodiments and drawings. The embodiments are for illustrative purposes only and are not intended to limit the present invention.

[0030] Embodiment 1:

[0031] The mouse epidermal growth factor composition of the present invention is prepared by the following steps:

[0032] 1. Rough extraction:

[0033] At 4°C-25°C, the mouse submandibular gland was thawed with glacial acetic acid, and the supernatant was obtained by multiple centrifugation and mixed for later use; the protein was separated by ammonium sulfate precipitation method, and the crude protein extract was obtained by ultrafiltration and concentration.

[0034] 2. Cation exchange chromatography I:

[0035] The crude protein extract was filtered after adjusting its pH to 5.0-7.0. The filtrate was applied to a cation exchange chromatography column I and the column was washed with a HAc-NaAc buffer solution at pH 5.0-7.0. Figure 1The target peak (sample collection-sample collection end) was selected and filtered to obtain the filtrate.

[0036] 3. Cation exchange chromatography II:

[0037] Prepare 0.02M pH3.0-4.0 HAc-NaAc buffer solution, record as A solution, prepare 0.02M pH3.0-4.0 HAc-NaAc buffer solution containing 0.5M NaCl, record as B solution. The filtrate collected in the previous step is loaded on the cation exchange chromatography column II. First use A solution for balance, then use A solution and B solution for gradient elution, and collect Figure 2 The peak E5 is the peak of interest. After ultrafiltration, the liquid in the ultrafiltration tube is collected, which is the mouse epidermal growth factor composition obtained by the present invention, and is recorded as E5-P.

[0038] The non-reducing SDS-PAGE image of the obtained mouse epidermal growth factor composition (E5-P) is as follows: Figure 3 As shown, it includes mouse epidermal growth factor and the other two proteins, E5-P, which appears as three bands in non-reducing SDS-PAGE, and the molecular weights are determined to be 40-55 kDa, 25-35 kDa, and 10-15 kDa, respectively.

[0039] Application Example 1:

[0040] Detecting the effect of the mouse epidermal growth factor composition E5-P on N87 human gastric cancer cells comprises the following steps:

[0041] 1. Inoculate N87 cells in a 96-well plate at a density of 20-50*10 4 / ml, 50-100 / well, culture for 24 hours.

[0042] 2. Dilute the E5-P prepared in Example 1 to 10 concentrations: 604 nM, 453 nM, 302 nM, 100 nM, 33 nM, 11 nM, 3.6 nM, 1.2 nM, 0.4 nM, 0.1 nM. Add 50 ul of sample to each cell well.

[0043] 3. Place the 96-well cell culture plate in a CO2 incubator and culture for 72 hours.

[0044] 4. Add 100 μl of culture medium solution containing 10% CCK-8 to the 96-well cell culture plate and incubate in a 37°C, 5% carbon dioxide incubator for 1.5-2.5 hours. OD450 readings and anti-tumor activity curves are shown in Figure 4 IC 50 =9.302nM.

[0045] The above results indicate that the mouse epidermal growth factor composition of the present application has excellent anti-tumor ability and can be used for the treatment of gastric cancer.

[0046] Application Example 2:

[0047] Detecting the effect of the mouse epidermal growth factor composition E5-P on 3T3 mouse fibroblasts comprises the following steps:

[0048] 1. Inoculate 3T3 cells in a 96-well plate at a density of 1-8*10 4 / ml, 50-100ul / well, culture for 24 hours.

[0049] 2. Dilute the E5-P prepared in Example 1 to 10 concentrations: 604 nM, 453 nM, 302 nM, 100 nM, 33 nM, 11 nM, 3.6 nM, 1.2 nM, 0.4 nM, 0.1 nM. Add 50 ul of sample to each cell well.

[0050] 3. Place the 96-well cell culture plate in a CO2 incubator and culture for 72 hours.

[0051] 4. Add 100 μl of culture medium solution containing 10% CCK-8 to the 96-well cell culture plate and incubate in a 37°C, 5% carbon dioxide incubator for 1.5-2.5 hours. OD450 readings, the experimental results are shown in Table 1.

[0052] Table 1 Effect of mouse skin growth factor composition on 3T3 cells detected by CCK-8

[0053] E5-P concentration (nm) OD450 604 2.0180 453 2.0120 302 1.9160 100 2.0585 33 2.1235 11 2.0550 3.6 2.1340 1.2 2.1215 0.4 2.2180 0.1 2.2295

[0054] The results showed that E5-P had no significant inhibitory or growth-promoting effect on 3T3 cells at 0.1nM-604nM.

[0055] Comparative Example 1:

[0056] The MTT method was used to detect the effect of pure mouse epidermal growth factor (mEGF) on 3T3 mouse fibroblasts, including the following steps:

[0057] 1. Inoculate 3T3 cells in a 96-well plate at a density of 1.0 × 10 4 ~8.0×10 / ml, 50-100ul / well, culture for 24 hours.

[0058] 2. Dilute mEGF to 8 concentrations: 297.3nM, 74.325nM, 18.581nM, 4.645nM, 1.161nM, 0.290nM, 0.072nM, 0.018nM. Discard the culture medium of the 96-well plate and add 50-100ul sample to each cell well.

[0059] 3. Place the 96-well cell culture plate in a CO2 incubator and culture for 72 hours.

[0060] 4. Add 20ul of MTT solution to each well of the 96-well cell culture plate and incubate in a 37°C, 5% carbon dioxide incubator for 5 hours.

[0061] 5. After the incubation, remove the liquid from the culture plate, add 100ul / well of dimethyl sulfoxide, and read the OD570 at 630nM as the reference wavelength. The experimental results are shown in Figure 5 .

[0062] The results showed that pure mouse epidermal growth factor (mEGF) had a significant growth-promoting effect on 3T3 mouse fibroblasts at 0.018nM-297.3nM; combined with the conclusion of Application Example 2, it can be seen that the mouse epidermal growth factor composition (E5-P) prepared in this application and mEGF are different products, and their effects are completely different.

[0063] Comparative Example 2:

[0064] The CCK-8 method was used to detect the effect of pure mouse epidermal growth factor (mEGF) on N87 human gastric cancer cells, including the following steps:

[0065] 1. Inoculate N87 cells in a 96-well plate at a density of 20-50*10 4 / ml, 50-100ul / well, culture for 24 hours.

[0066] 2. Dilute mEGF to 8 concentrations: 118nM, 39.33nM, 13.11nM, 4.37nM, 1.46nM, 0.49nM, 0.16nM, 0.05nM, 0.02nM, 0.01nM. Add 50ul sample to each cell well.

[0067] 3. Place the 96-well cell culture plate in a CO2 incubator and culture for 72 hours.

[0068] 4. Add 100 μl of culture medium solution containing 10% CCK-8 to the 96-well cell culture plate and incubate in a 37°C, 5% carbon dioxide incubator for 1.5-2.5 hours. OD450 reading, experimental results are shown in Figure 6 .

[0069] The results showed that pure mouse epidermal growth factor (mEGF) at 0.01nM-118.00nM mainly promoted the growth of N87 human gastric cancer cells. Combined with the conclusion of Application Example 1, it can be seen that the mouse epidermal growth factor composition (E5-P) prepared in this application has completely different effects from mEGF. The synergistic effect between the proteins in the composition shows excellent anti-tumor effect and can be used for the treatment of gastric cancer.

[0070] The scope of the present disclosure is not limited by the specific embodiments, which are intended to be a single illustration of various aspects of the present disclosure, and any composition or method that is functionally equivalent is included within the scope of the present disclosure. It is apparent to those skilled in the art that various modifications and variations may be made to the methods and compositions of the present disclosure without departing from the spirit or scope of the present disclosure. Therefore, the present disclosure is intended to cover modifications and variations of the present disclosure as long as they are within the scope of the appended claims and their equivalents.

Claims

1. The use of a mouse epidermal growth factor composition in the preparation of a drug for treating cancer, characterized in that: The mouse epidermal growth factor composition presents three bands in non-reducing SDS-PAGE, and the measured molecular weights are 40-55 kDa, 25-35 kDa, and 10-15 kDa, respectively.

2. The use according to claim 1, characterized in that: The cancer is gastric cancer.

3. A mouse epidermal growth factor composition, characterized in that: The mouse epidermal growth factor composition presents three bands in non-reducing SDS-PAGE, and the measured molecular weights are 40-55 kDa, 25-35 kDa, and 10-15 kDa, respectively.

4. A mouse epidermal growth factor preparation, characterized in that: The preparation contains a safe and effective amount of the mouse epidermal growth factor composition according to claim 3.

5. The mouse epidermal growth factor preparation according to claim 4, characterized in that The preparation further comprises an auxiliary material or a pharmaceutically acceptable carrier.

6. An anticancer drug, characterized in that: The active ingredient of the medicine includes the mouse epidermal growth factor composition according to claim 3.

7. The anticancer drug according to claim 6, characterized in that The drug further comprises an auxiliary pharmaceutically acceptable carrier.

8. The anticancer drug according to claim 6 or 7, characterized in that: The cancer is gastric cancer.

Citation Information

Patent Citations

  • Method for purifying epidermal growth factor

    CN117024558A

  • Rat epidermal growth factor preparation and preparation method thereof

    CN117417428A